Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Scientific Contributions

Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men

Roberto Pedrinelli, Giulia Dell’Omo, Giuseppe Penno, Simona Bandinelli, Alessio Bertini, Vitantonio Di Bello, Mario Mariani
Download PDF
https://doi.org/10.1161/01.HYP.35.1.48
Hypertension. 2000;35:48-54
Originally published January 1, 2000
Roberto Pedrinelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giulia Dell’Omo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Penno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simona Bandinelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessio Bertini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vitantonio Di Bello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Mariani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract—To identify the biological covariates of microalbuminuria (albuminuria ≥15 μg/min) in nondiabetic subjects, brachial blood pressure, echocardiographic left ventricular mass, and other cardiovascular and metabolic parameters were evaluated in 211 untreated males (38 normal controls, 109 uncomplicated stage 1 to 3 essential hypertensives, and 64 patients with clinically stable atherosclerotic peripheral vascular disease either with [n=44] or without [n=20] essential hypertension) with normal cardiac and renal function. Compared with normoalbuminuric subjects, microalbuminuric subjects (n=67) were characterized by higher systolic blood pressure, comparable diastolic blood pressure, and, therefore, wider pulse pressure. Greater prevalence of hypertension, peripheral vascular disease, left ventricular hypertrophy, and reduced HDL cholesterol values further distinguished microalbuminuric from normoalbuminuric subjects in univariate comparisons. The risk of microalbuminuria increased by ascending pulse pressure quintiles in age-corrected logistic regression models, in which pulse pressure was more predictive than systolic pressure and was independent of mean pressure. When microalbuminuric status was regressed against a series of dichotomous (vascular and active smoker status) and continuous (age, pulse and mean pressure, left ventricular mass index, and HDL and LDL cholesterol) variables, only pulse pressure, left ventricular mass index, and smoking status were independent predictors. The association of increased albuminuria with wider pulse pressure, a correlate of the pulsatile hemodynamic load and conduit vessel stiffness as well as an important cardiovascular risk factor, may explain why microalbuminuria predicts cardiovascular events in nondiabetic subjects. The independence from concomitant vascular disease also suggests that wider pulse pressure, rather than representing a simple marker for atherosclerotic disease, influences albuminuria directly.

  • albuminuria
  • pressure
  • hypertension, essential
  • vascular diseases
  • mass, ventricular

Microalbuminuria (ie, an abnormal urinary albumin excretion [UAE] in a range not detectable by the usual dipstick methods for urine protein) is associated with an increased cardiovascular risk in hypertensive patients1,2 and nondiabetic populations.3 4 5 Yet, why a renal parameter of glomerular origin behaves as a marker of atherosclerotic cardiovascular disease remains obscure, and the biological factors influencing UAE still await some deeper clarification.

To specify to a better extent the biological covariates of microalbuminuria in nondiabetic subjects, we have evaluated cross-sectionally a series of cardiovascular and metabolic parameters in a large group of normal control subjects, subjects with essential hypertension (EH), and patients with atherosclerotic vascular disease.

Methods

Subjects

The study was carried out on 211 eligible sedentary subjects referred to our unit from 1996 to 1998 for screening and treatment of hypertension and related cardiovascular risk factors. Inclusion criteria required male gender, negative urine dipstick test, normal urinary sediment and renal ultrasound, plasma glucose <7.8 mmol/L (120 mg/dL), serum creatinine <110 μmol/L (1.4 mg/dL), total serum cholesterol <7.8 mmol/L (300 mg/dL), body mass index (BMI) <27 kg/m2, and preserved systolic cardiac function (ejection fraction >50%) (see Table 1⇓ for the overall demographic and clinical characteristics). One hundred nine patients had stage 1 to 3 uncomplicated EH, 20 had atherosclerotic peripheral vascular disease (PVD), and 44 were affected by both conditions (EH/PVD). Thirty-eight normal subjects were the controls.

View this table:
  • View inline
  • View popup
Table 1.

Demographics and Clinical Characteristics of the 211 Subjects of the Sample

Clinical screenings were based on history, physical examination, routine tests, and neck and lower limb color-echo Doppler sonography in most subjects. All parameters reported in the present study were collected in a 2-week period.

Diagnosis of hypertension was based on casual blood pressure (BP) values >140/90 mm Hg and/or antihypertensive treatment at the first contact, and secondary forms of hypertension were excluded by routine examinations, including renal color-echo Doppler sonography and, if needed, angiography. If patients had received treatment, antihypertensive drugs were withdrawn 4 weeks before the study; no patient had ever been on lipid-lowering drugs. PVD was diagnosed by intermittent claudication (pain-free walking distance >200 m on a treadmill) confirmed by ankle-brachial pressure measurements <0.9 at one or both sides. According to institutional guidelines, subjects were aware of the investigational nature of the study and agreed to participate. The study was carried out in accordance with the Declaration of Helsinki, and the protocol was approved by the local Ethical Committee.

Experimental Procedures

UAE was measured by nephelometry (Behring; limit of detection 0.1 mg/dL, interassay variation coefficient 3.5%) on samples collected from 8:00 pm to 8:00 am during 3 consecutive days. Sitting BP was measured in the early afternoon by an automated oscillometric device (SpaceLabs 90207) throughout a 2-hour period. Wall thickness and chamber diameters were determined at or just below the mitral valve tips, by the leading edge–to–leading edge method on monodimensional and bidimensional echocardiograms (Hewlett Packard Sonos 1000, with 2.5- and 3.5-MHz transducers) according to recommendations of the American Society of Echocardiography. Clinically significant aortic insufficiency was excluded in all subjects by Doppler examinations. Anthropometric measurements (height and weight) were made after each participant had removed his shoes and upper garments. Blood samples were obtained between 8:00 and 9:00 am after an overnight fasting and 15 minutes of supine rest. Total cholesterol, HDL cholesterol, and triglycerides were assessed by enzymatic colorimetric techniques (Boehringer-Mannheim). Serum and urine creatinine levels were assayed by standard colorimetric methods.

Data Processing

UAE (μg/min) was the median of 3 consecutive overnight collections (median variation coefficient 25%). Microalbuminuria was defined as any UAE value ≥15 μg/min6 in the presence of a negative dipstick test for urine protein. Systolic BP (SBP) and diastolic BP (DBP) values were the mean of at least 10 recordings taken over a 2-hour period. Pulse pressure (PP) was the arithmetic difference between averaged SBP and DBP values. Mean BP (MBP) was DBP +1/3 PP. BMI (body weight/squared surface area), creatinine clearance, and LDL cholesterol [total cholesterol−(HDL cholesterol+triglyceride/5)] were calculated from standard formulas. Smoking status was defined as active smokers versus nonsmokers, without distinction between former smokers and those who have never smoked.

Left ventricular mass (Penn convention) was corrected for height to derive the left ventricular mass index (LVMI, g/m). Myocardial hypertrophy was defined as LVMI ≥143 g/m, a partition value associated with all-cause mortality and sudden death in population-based investigations.7 8 Stroke volume (SV) was the difference between end-diastolic and end-systolic left ventricular volume.

Statistics

The association of microalbuminuria (coded as follows: 0, normoalbuminuria; 1, microalbuminuria) with continuous and categorical (including quintiles of PP) covariates was analyzed by logistic regression (maximum likelihood method) using a backward stepwise procedure (probability to remove, P<0.05) to identify the independent regressors. Odds ratios (ORs, ie, the exponentiated regression coefficients) were used to estimate relative risks and 95% CIs. Intraindividual association of continuous variables was evaluated by nonparametric Spearman rank correlation coefficients. Differences among continuous variables were tested by ANOVA covariated for age, and a multiple range test was used to evaluate differences among means. Categorical parameters were tested by Cochran-Armitage exact tests.

Data were reported as mean±1 SD or median and range in the presence of skewed data. Statistical significance was set at P<0.05 unless otherwise indicated.

Results

Clinical Characteristics by Microalbuminuric Status

Older age, higher SBP, comparable DBP, wider PP with the same SV, greater prevalence of hypertension, atherosclerotic PVD, cardiac hypertrophy, higher LVMI and MBP, and lower HDL cholesterol values distinguished microalbuminuric subjects (median UAE 28 [range 15 to 271] μg/min, n=67) from normoalbuminuric subjects (median UAE 7 [range 2 to 14] μg/min, n=144) (Table 2⇓). Differences in smoking status and LDL cholesterol were of borderline (P<0.1) significance.

View this table:
  • View inline
  • View popup
Table 2.

Age-Corrected Comparisons of Cardiovascular, Renal, and Metabolic Parameters in Subjects With and Without Microalbuminuria

Clinical Characteristics by Vascular Status

Irrespective of BP, subjects with arteriopathy were older and had a more atherogenic lipid profile. Clinical characteristics of the study subjects are shown in Table 3⇓.

View this table:
  • View inline
  • View popup
Table 3.

Cardiovascular, Renal, and Metabolic Parameters According to Vascular Status (EH, PVD, and EH/PVD)

Compared with patients with EH, patients with EH/PVD showed a greater frequency of microalbuminuria, higher UAE and SBP, lower DBP, wider PP, and similar MBP.

Cardiovascular parameters did not differ between normotensive PVD patients and controls.

Intraindividual Correlations

Age-related influences were most evident on creatinine clearance (inversely, r=−0.44, P<0.001), PP (r=0.40, P<0.001), and, in decreasing order, SBP (r=0.23, P<0.001), UAE (r=0.20, P<0.004), and LVMI (r=0.18, P<0.01). Lipids and DBP were independent of age.

UAE was correlated with PP (Figure 1⇓), SBP (r=0.38 for both, P<0.001), MBP (r=0.28, P<0.001), and, to a lower extent, DBP (r=0.18, P<0.02). Other statistically significant covariates of albuminuria were LVMI (r=0.21, P<0.01), total cholesterol (r=0.14, P<0.05), LDL cholesterol (r=0.21, P<0.01), and HDL cholesterol (inversely, r=−0.22, P<0.01).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Plot of UAE (log scale) vs PP. The rank correlation coefficient was 0.38 (P<0.001, n=211).

PP was closely correlated with SBP (r=0.75, P<0.001) and MBP (r=0.43, P<0.001) but not DBP (r=0.10). Systolic and diastolic values were also correlated (r=0.69, P<0.001). The rank correlation of PP and SBP with LVMI was 0.17 (P<0.01) and 0.33 (P<0.001), respectively.

Risk of Microalbuminuria by PP Quintiles

The proportion of subjects with microalbuminuria (Figure 2⇓, left panel; P<0.001) and their UAE levels (Figure 2⇓, right panel; P<0.007) increased by increasing PP quintiles (cutoff points 45, 50, 59, and 68 mm Hg; n=40, 39, 46, 43, and 43).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Percentage of patients with microalbuminuria (left) and UAE values (right) by PP quintiles (cutoff points 45, 50, 59, and 68 mm Hg; n=40, 39, 46, 43, 43). To provide adequate information about the skewed UAE distribution, results are presented as box-and-whisker plots. The central box encloses the middle 50% of the data, the horizontal line inside the box represents the median, and the mean is plotted as a cross. Vertical lines (whiskers) extend from each end of the box and cover 4 interquartile ranges. Points indicate outliers.

The age-corrected risk of microalbuminuria did not differ from 1 in the intermediate PP quintiles and increased by 3.4-fold (95% CI 1.24 to 9.3, P<0.03) and 5.3-fold (95% CI 1.9 to 15, P<0.003) in the fourth and fifth quintile, respectively (Figure 3⇓). The trend did not change when PVD patients were excluded from the analysis (cutoff points 44, 50, 54, and 60 mm Hg; n=29, 28, 30, 30, and 30; OR of the upper quintile versus baseline 5.8; 95% CI 1.41 to 24; P<0.02, n=147).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Age-corrected risk of microalbuminuria by PP quintiles. Ninety-five percent CIs are reported at the top of each histogram (n=211). For statistics, see text.

Pulsatile and Steady BP Components and Risk of Microalbuminuria

The relative importance of PP, SBP, DBP, and MBP in predicting microalbuminuria was addressed in logistic regression models, including BP parameters alone and in combination. Because age was an univariate predictor of microalbuminuria risk (OR 1.39/10 years, 95% CI 1.05 to 1.56, P<0.01), all analyses included age as a covariate.

PP, as such, was associated (P<0.001) with a 62% increase in risk for every 10 mm Hg rise (95% CI 1.35 to 1.9) compared with a 41% increase for every 10 mm Hg rise in SBP (95% CI 1.22 to 1.59, P<0.001). When PP and SBP were combined, PP remained a significant (P<0.03) predictor of microalbuminuria (OR/10 mm Hg increase 1.43, 95% CI 1.03 to 1.83), and SBP did not (OR/10 mm Hg increase 1.17, 95% CI 0.99 to 1.45, P<0.2). The risk associated with PP (OR/10 mm Hg increase 1.55, 95% CI 1.26 to 1.85, P<0.001) was independent of MBP (OR/10 mm Hg increase 1.17, 95% CI 0.99 to 1.5, P<0.2); when evaluating SBP and DBP in the same model, higher SBP (OR/10 mm Hg increase 1.61, 95% CI 1.34 to 1.89, P<0.001) and lower DBP (OR/10 mm Hg decrease 0.096, 95% CI 0.092 to 0.099, P<0.03) predicted microalbuminuria.

Multivariate Components of the Risk of Microalbuminuria

Among the dichotomous (vascular and active smoker status) and continuous (age, PP, MBP, LVMI, and HDL and LDL cholesterol) variables that distinguished (P<0.1) microalbuminuric from normoalbuminuric subjects in one-to-one comparisons, only PP (OR/10 mm Hg rise 1.6, 95% CI 1.3 to 1.9, P<0.001), LVMI (OR/10 g/m 1.14, 95% CI 1.03 to 1.25, P<0.02), and smoking (OR 1.97, 95% CI 1.001 to 3.98, P=0.05) predicted microalbuminuria independently (Figure 4⇓). The overall percentage of deviance explained by the model was 18%.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Risk of microalbuminuria by increasing PP, LVMI, and smoking status according to a multivariate logistic model [(Exp− 6.28+0.058×PP+0.014×LVMI+0.68×smoking status/1+Exp−6.28+0.058×PP+0.014×LVMI+0.68×smoking status)×100]. For statistics, see text. The 12% risk of microalbuminuria of a nonsmoker male (PP 50 mm Hg, LVMI 100 g/m) contrasts with the 65% risk of an active smoker male (PP 70 mm Hg, LVMI 150 g/m).

Discussion

The original finding of this cross-sectional evaluation of the biological covariates of microalbuminuria in a large and carefully screened group of nondiabetic males was the independent predicting power of a wider PP, a readily obtainable measure of pulsatile flow,9 10 in contrast with the lack of statistical weight of MBP, a surrogate measure of steady flow,9 10 examined simultaneously with PP. The risk profile associated with progressive PP widening did not differ from 1 in the intermediate range of values and increased sharply only at ≈≥60 mm Hg. A nonlinear trend implies that a threshold exists above which the renal impact of that hemodynamic factor becomes more evident and, reciprocally, that its influence may be obscured by other biological mechanisms at lower PP levels. PP also provided information additional to SBP, in spite of the strict collinearity between the 2 parameters. Risk of microalbuminuria was predicted by both lower DBP and higher SBP entered in the same logistic regression model, indicating that PP compounded the exaggerated rises in the latter and the less than proportional increments or actual decrements in the former. Determinants of PP include SV, rate of systolic ejection, and stiffness of the arterial tree.9 10 Because SV measurements did not vary across the spectrum of UAE values, increased arterial stiffness was a more likely cause of the wider PP in our microalbuminuric subjects, probably because of arteriosclerotic degeneration of the major capacitance arteries, although other mechanisms cannot be ruled out on the basis of our data.11

An obvious question regards confounders, primarily atherosclerosis, a disease in which segmental macrovascular lesions and diffuse microvascular abnormalities tend to coexist,12 affecting about one third of the components of our sample. Atherosclerosis may also increase UAE by damaging diffusely vascular endothelium,13 but our finding of a normal UAE in the group of normotensive patients with a fully developed arterial lower limb disease, in itself a harbinger of widespread macroangiopathy,14 does not support that prediction. It was only in the presence of an exaggerated PP, a likely result of the stiffening of large arteries through collagen neoformation and excess calcium deposition at the affected sites,11 15 that the prevalence of microalbuminuria increased strikingly. Our data, therefore, suggest an only indirect relation between atherosclerotic macroangiopathy and renal microvascular changes, with elevated BP, particularly its pulsatile elements, acting as the chain in the link; however, our data do confirm that subclinical kidney damage is frequent in EH that is complicated by PVD.3 16 The increasing prevalence of microalbuminuria by ascending PP quintiles in uncomplicated subjects analyzed separately from atherosclerotic patients and the overall results of the multivariate logistic regression analyses further discount a direct link between advanced atherosclerosis and albuminuria, in agreement with data from our17 and other18 laboratories. This negative conclusion contrasts with the inferences drawn from the results of previous cross-sectional observations of patients with atherosclerotic PVD,3 perhaps because uninterrupted antihypertensive treatment may have obscured pressure-related effects in that later study. Age-related confounding could also be hypothesized because, as expected,19 PP and, to a lesser extent, even UAE showed age-related changes, but demographic differences between normoalbuminuric and microalbuminuric subjects were not huge, and, besides, statistics accounted for this factor. Cardiovascular risk factors such as dyslipidemia, diabetes, and smoking may influence both UAE20 and conduit vessel distensibility,10 but total and LDL cholesterol values were evenly distributed, and HDL cholesterol, albeit reduced in the present and in a previous study20 of microalbuminuric subjects, did not emerge as a critical factor in the statistical analyses. Furthermore, diabetics were excluded from the trial, and the albuminuric action of smoking, already shown in past studies21 22 and confirmed in the present study, was additive to that of PP. Thus, the strength of statistical association, its persistence after adjusting for potential confounders, and inferential reasoning make plausible a direct connection between microalbuminuria and elevated PP. Similar results were obtained in the studies that examined the behavior of PP23 24 and, more frequently, SBP (a measure of vascular compliance25 and a variable strictly related to PP) as determinants of albuminuria in unselected populations26,27 and hypertensive patients.22,28 Regarding mechanisms, an excessive pulsatile load altered gluteal arteriolar structure,29 and the same may happen at the renal level, where wall hypertrophy characterized the nephrosclerotic biopsies harvested from mildly proteinuric EH patients.30 In light of the recent demonstration of the relation between microalbuminuria and future development of renal insufficiency in EH,2 it may be relevant, in this context, to consider the independent association between increasing serum creatinine and faster pulse-wave velocity, a measure of arterial stiffness, in EH patients.31 SBP also frequently overcame DBP as a predictor of overt kidney damage and end-stage renal disease,32 a clinical condition in which arterial stiffness is almost universal.33 Cross-sectional associations are to be taken with caution, though, and we are aware that our present cross-sectional findings might be compatible with exactly opposite interpretations, eg, an effect of urine albumin on PP. Prospective follow-ups of populations (less selected than ours and mainly composed of subjects referred to a tertiary diagnostic center) will be needed to evaluate in further detail any role of the pulsatile BP components on the kidney. The discrepancy between overnight measurement of urine and early afternoon BP recordings or gender-related phenomena in our all-male group should also be considered. Technical limits may also exist in that peripheral and central PPs differ to a variable extent,9 which is not a critical point, though, in view of the fact that differences in hemodynamic regimens are attenuated in middle-aged sedentary subjects.9

Because brachial PP determination predicts morbid events in prospective cohorts of essential hypertensive subjects,34 35 our data may help to understand better why microalbuminuria behaves as a marker of cardiovascular risk in nondiabetic hypertensive subjects. Moreover, the association with other primary risk factors, such as increased LVMI and left ventricular hypertrophy, decreased HDL cholesterol levels, and tobacco smoking, legitimately qualifies microalbuminuria as an integrated marker of cardiovascular risk. The list of damaging factors associated with the presence of microalbuminuria may, however, be incomplete; as a matter of fact, additional mechanisms are likely (eg, see References 21 and 3621 36 ), in view of the fact that our logistic model left ≈80% of the total microalbuminuria deviance unexplained. Furthermore, our cardiac mass data confirm the correlation with UAE,37 an association usually interpreted as a reflection of the prevailing pressor load on the kidney and the heart. Quite unexpectedly, however, the statistical link between the 2 parameters was independent of pressure, a result also recently reported by Gatzka et al.38 The data might perhaps be explained by circulating factors that are produced in greater amount by a hypertrophic heart39 and by an increasing renal permeability to albumin.40 This interesting possibility requires further evaluation in future studies.

In conclusion, the association of increased albuminuria with wider PP, a correlate of the pulsatile hemodynamic load and conduit vessel stiffness, which is in itself an important cardiovascular risk factor, and left ventricular hypertrophy may help to explain why microalbuminuria predicts cardiovascular events in nondiabetic subjects. The independence from concomitant vascular disease also suggests that wider PP, rather than representing a simple marker for atherosclerotic disease, influences albuminuria directly.

Footnotes

  • Reprint requests to Roberto Pedrinelli, MD, Dipartimento Cardiotoracico, Università di Pisa, 56100 Pisa, Italy.

  • Received July 1, 1999.
  • Revision received July 16, 1999.
  • Accepted August 18, 1999.

References

  1. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: a population-based study of 1254 hypertensive individuals. J Hum Hypertens. 1997;11:727–732.
    OpenUrlCrossRefPubMed
  2. ↵
    Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16:1325–1333.
    OpenUrlCrossRefPubMed
  3. ↵
    Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non diabetic subjects. Lancet. 1988;ii:530–533.
  4. ↵
    Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91:831–837.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ. 1990;300:297–300.
  6. ↵
    Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Jensen G. Urinary albumin excretion in a population based sample of 1011 middle aged non diabetic subjects: the Copenhagen City Heart Study Group. Scand J Clin Lab Invest. 1993;53:867–872.
    OpenUrlPubMed
  7. ↵
    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med. 1990;322:1561–1566.
    OpenUrlCrossRefPubMed
  8. ↵
    Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk of sudden death. J Am Coll Cardiol. 1998;32:1454–1459.
    OpenUrlCrossRefPubMed
  9. ↵
    Smulyan H, Safar ME. Systolic blood pressure revisited. J Am Coll Cardiol. 1997;29:1407–1413.
    OpenUrlCrossRefPubMed
  10. ↵
    Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AJ, Morgan DJ, Cohn JN. Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens.. 1997;10:1175–1189.
    OpenUrlCrossRefPubMed
  11. ↵
    Benetos A, Laurent S, Asmar RG, Lacolley P. Large artery stiffness in hypertension. J Hypertens. 1997;15(suppl 2):S89–S97.
  12. ↵
    Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwin AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71b–74b.
  13. ↵
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219–226.
    OpenUrlCrossRefPubMed
  14. ↵
    Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241–245.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Safar ME, Toto-Moukomo JJ, Bouthier JA, Asmar RA, Laurent SM. Increased pulse pressure in patients with arteriosclerosis obliterans of the lower limbs. Arteriosclerosis. 1987;7:232–237.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Fabsitz RR, Sidaway AN, Go O, Lee ET, Weity TK, Devereux RB, Howard BV. Prevalence of peripheral arterial disease and associated risk factors in American Indians. Am J Epidemiol. 1999;149:330–338.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Pedrinelli R, Penno G, Dell’Omo G, Bandinelli S, Giorgi D, Di Bello V, Nannipieri M, Navalesi R, Mariani M. Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. Hypertension. 1998;32:312–318.
    OpenUrl
  18. ↵
    Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CDA. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617–624.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Franklin SS, Gustin W, Wong ND, Larson MGF, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation. 1997;96:308–315.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int. 1999;56(suppl 71):S10–S13.
  21. ↵
    Pedrinelli R, Giampietro O, Carmassi O, Melillo E, Dell’Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18.
    OpenUrlCrossRefPubMed
  22. ↵
    Mimran A, Ribstein J, Du Cailar G, Halimi JM. Albuminuria in normals and essential hypertension. J Diabetes Complications. 1994;8:150–156.
    OpenUrlCrossRefPubMed
  23. ↵
    Clausen P, Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Ambulatory blood pressure and urinary albumin excretion in clinically healthy subjects. Hypertension. 1998;32:71–77.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Kasiske BL, Rith-Najarian S, Casper ML, Croft JB. American Indian heritage and risk factors for renal injury. Kidney Int. 1998;54:1305–1310.
    OpenUrlCrossRefPubMed
  25. ↵
    Safar ME, St Laurent S, Safavian AL, Pannier BM, London GM. Pulse pressure in sustained essential hypertension: a haemodynamic study. J Hypertens. 1987;5:213–218.
    OpenUrlCrossRefPubMed
  26. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W, De Santo NG. Microalbuminuria in non diabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels and smoking: the Gubbio population study. Arch Int Med. 1998;158:1933–1939.
    OpenUrlCrossRefPubMed
  27. Goetz FC, Jacobs DR, Chavers B, Roel J, Yelle M, Sprafka JM. Risk factors for kidney damage in the adult population of Wadena, Minnesota: a prospective study. Am J Epidemiol. 1997;145:91–102.
    OpenUrlAbstract/FREE Full Text
  28. Agewall S, Fagerberg B. Risk factors that predict development of microalbuminuria in treated hypertensive men: the Risk Intervention Study Group. Angiology. 1996;47:963–972.
  29. ↵
    James MA, Watt PAC, Potter JF, Thurston H, Swales JD. Pulse pressure and resistance artery structure in the elderly. Hypertension. 1995;26:301–306.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) trial. Kidney Int. 1997;51:244–252.
    OpenUrlCrossRefPubMed
  31. ↵
    Blacher J, Asmar R, Saliha D, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111–1117.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Whelton PK, Perneger TV, He J, Klag MJ. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens. 1996;10:683–689.
    OpenUrlPubMed
  33. ↵
    London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 1997;51:1678–1995.
    OpenUrlPubMed
  34. ↵
    Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension. 1998;32:560–564.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998;32:983–988.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int. 1998;54:203–209.
    OpenUrlCrossRefPubMed
  37. ↵
    Pedrinelli R, Di Bello VA, Catapano G, Talarico L, Materazzi F, Santoro G, Giusti C, Mosca F, Melillo E, Ferrari M. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in non diabetic atherosclerotic patients. Arterioscler Thromb. 1993;13:900–906.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Gatzka CD, Reid CM, Lux A, Dart AM, Jennings G. Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure: Hypertension Diagnostic Service Investigators. Clin Exp Pharmacol Physiol. 1999;26:514–516.
    OpenUrlCrossRefPubMed
  39. ↵
    Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996;28:22–30.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Mc Murray J, Seidelin PH, Howey JE, Balfour DJ, Struthers AD. The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man. J Hypertens. 1988;6:783–786.
    OpenUrlPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
January 2000, Volume 35, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men
    Roberto Pedrinelli, Giulia Dell’Omo, Giuseppe Penno, Simona Bandinelli, Alessio Bertini, Vitantonio Di Bello and Mario Mariani
    Hypertension. 2000;35:48-54, originally published January 1, 2000
    https://doi.org/10.1161/01.HYP.35.1.48

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men
    Roberto Pedrinelli, Giulia Dell’Omo, Giuseppe Penno, Simona Bandinelli, Alessio Bertini, Vitantonio Di Bello and Mario Mariani
    Hypertension. 2000;35:48-54, originally published January 1, 2000
    https://doi.org/10.1161/01.HYP.35.1.48
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured